Boston Scientific to Release Broad Range of Clinical Results on Endoscopic Technologies at DDW® 2006

Physicians offer preview of SpyGlass™ Direct Visualization System

PRNewswire-FirstCall
NATICK, Mass. (NYSE:BSX)

NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at Digestive Disease Week® (DDW®), which runs from May 20 to 25 in Los Angeles. Boston Scientific will be announcing results from several clinical studies, aimed to determine the safety and effectiveness of leading endoscopic technologies including the Polyflex® Esophageal Stent and the Resolution® Clip. Physicians will also share results from the first human use clinical series and bench simulation study of Boston Scientific's SpyGlass™ Direct Visualization System.

"The data we present at DDW support the effectiveness of our leading endoscopic technologies in managing patients with esophageal and gastrointestinal diseases," said Michael P. Phalen, President, Boston Scientific Endoscopy. "Innovative treatment options, such as the Polyflex Esophageal Stent and Resolution Clip, aim to improve patients' quality of life through a less-invasive approach."

Schedule of Events (Partial Listing)

Please note that the data is embargoed until the beginning of each session.

Sunday, May 21 (all times are PT)

* Resolution Hemoclip for GI bleeding.
   The Company will announce results of a study to determine the efficacy of using the Resolution Clip, an endoscopic mechanical clip, to treat gastrointestinal (GI) bleeding instead of traditional electrocautery and injection therapy. The poster presentation prepared by Mitchell Kaplan, M.D., and Sri Komanduri, M.D., M.S., titled "The Efficacy of the Resolution Hemoclip in Hemodynamically Significant Upper and Lower GI Bleeds: A Safe and Effective Alternative to Cautery" will be available from 8:00 a.m. - 5:00 p.m. in West Hall A of the Los Angeles Convention Center.

* Polyflex Stent in RNBES.
   The Company will announce results of a study to determine the efficacy of using the Polyflex Esophageal Stent to reduce the number of dilations to relieve dysphagia caused by resilient non-peptic benign esophageal strictures (RNBES). The poster presentation prepared by Rajesh Santharam, M.D., and Kulwinder S. Dua, M.D., titled "Continuous Non-Permanent Dilation of Resilient Non-Peptic Benign Esophageal Strictures Using a Self-Expanding Plastic Esophageal Stent (Polyflex®): A Prospective Study" will be available from 8:00 a.m. - 5:00 p.m. in West Hall A.

Monday, May 22

* SpyGlass™ Direct Visualization System.
   At 4:00 p.m., an oral presentation titled "Pilot Evaluation of a Direct Visualization Probe for Intraductal Examination of the Biliary System" will be presented by Soren Meisner, M.D. in Room 511 A/B. Immediately
following at 4:12 p.m., results from the first human-use clinical series and bench simulation study of the SpyGlass Direct Visualization System will be presented by Yang K. Chen, M.D., during an oral presentation titled "Results From the First Human Use Clinical Series Utilizing a New Peroral Cholangiopancreatography System (SpyGlass Direct Visualization System)".

Tuesday, May 23

* Polyflex Stent in anastomotic strictures.
The Company will announce results of a study, which examined the placement of the Polyflex Esophageal Stent to determine its efficacy in managing patients with persistent anastomotic strictures (AS). The poster presentation prepared by James S. Barthel, M.D. et al., titled "Management of Persistent Gastroesophageal Anastomotic Strictures with Polyflex Stents: An Alternative to Serial Dilation" will be available from 8:00 a.m. - 5:00 p.m. in West Hall A.

* Hemoclip study for coumadin therapy patients.
At 3:15 p.m., the Company will announce results of a study designed to investigate the use of hemostatic clips in patients on coumadin® anticoagulation therapy (CAC) who undergo a colonoscopy. The results will be presented by Douglas A. Howell, M.D., during an oral session titled "Use of Hemostatic Clips in Patients Undergoing Colonoscopy in the Setting of Coumadin Anticoagulation Therapy", in Room 511 A/B/C.

Boston Scientific will issue trade-specific press releases covering all of the studies mentioned in the Company's schedule of events.

Boston Scientific will present its latest innovations at booth #1227, including the next generation of the market-leading, single-use biopsy forceps -- Radial Jaw® 4. The Company will also offer hands-on product demonstration sessions of the RX Biliary System™, Resolution Clip, Radial Jaw 4 Biopsy Forceps, and the Polyflex Esophageal Stent in its Simulated Clinical Endoscopy Suite.

About Digestive Disease Week®

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the Society for Surgery of the Alimentary Tract, DDW takes place May 20 - 25, 2006, in Los Angeles. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange